Septodont Further Enhances its Dental Portfolio
Septodont continues growth and expansion plans. The company confirmed an agreement with Sanofi to acquire a portfolio of 4 dental care brands and related medical devices.
The acquired portfolio includes high-quality medicines such as Ultracain®, Rodogyl®, Birodogyl®, and Dontisolon®, as well as related medical devices.
Septodont had announced its intent to acquire these brands in July 2021. Completion of the full transaction remains subject in some limited markets to a few customary approvals.
“We’re excited about this strategic acquisition, which marks an exciting new milestone for our dental business”, says Olivier Schiller, CEO of the Septodont’s Group. “These brands are great additions to our existing dental portfolio. They will allow us to strengthen the value proposition we bring to our customers through a broader range of products and solutions. This acquisition will also accelerate the pace of our geographic expansion in key European markets, particularly in Germany, as well as in several other key markets in Asia and North Africa”.
Consistent with our strategy, this acquisition will enable the company to continue to grow and compete in the dental space.
As a result of the acquisition, Septodont will invest in a state-of-the-art manufacturing facility at its Saint-Maur-des-Fossés site, in France, boosting local competitiveness and driving economic growth.
This investment demonstrates Septodont’s commitment to its manufacturing footprint in France and will support the local economic development with the creation of approximately 60 jobs.
Septodont continues growth and expansion plans. The company confirmed an agreement with Sanofi to acquire a portfolio of 4 dental care brands and related medical devices.
The acquired portfolio includes high-quality medicines such as Ultracain®, Rodogyl®, Birodogyl®, and Dontisolon®, as well as related medical devices.
Septodont had announced its intent to acquire these brands in July 2021. Completion of the full transaction remains subject in some limited markets to a few customary approvals.
“We’re excited about this strategic acquisition, which marks an exciting new milestone for our dental business”, says Olivier Schiller, CEO of the Septodont’s Group. “These brands are great additions to our existing dental portfolio. They will allow us to strengthen the value proposition we bring to our customers through a broader range of products and solutions. This acquisition will also accelerate the pace of our geographic expansion in key European markets, particularly in Germany, as well as in several other key markets in Asia and North Africa”.
Consistent with our strategy, this acquisition will enable the company to continue to grow and compete in the dental space.
As a result of the acquisition, Septodont will invest in a state-of-the-art manufacturing facility at its Saint-Maur-des-Fossés site, in France, boosting local competitiveness and driving economic growth.
This investment demonstrates Septodont’s commitment to its manufacturing footprint in France and will support the local economic development with the creation of approximately 60 jobs.
Septodont continues growth and expansion plans. The company confirmed an agreement with Sanofi to acquire a portfolio of 4 dental care brands and related medical devices.
The acquired portfolio includes high-quality medicines such as Ultracain®, Rodogyl®, Birodogyl®, and Dontisolon®, as well as related medical devices.
Septodont had announced its intent to acquire these brands in July 2021. Completion of the full transaction remains subject in some limited markets to a few customary approvals.
“We’re excited about this strategic acquisition, which marks an exciting new milestone for our dental business”, says Olivier Schiller, CEO of the Septodont’s Group. “These brands are great additions to our existing dental portfolio. They will allow us to strengthen the value proposition we bring to our customers through a broader range of products and solutions. This acquisition will also accelerate the pace of our geographic expansion in key European markets, particularly in Germany, as well as in several other key markets in Asia and North Africa”.
Consistent with our strategy, this acquisition will enable the company to continue to grow and compete in the dental space.
As a result of the acquisition, Septodont will invest in a state-of-the-art manufacturing facility at its Saint-Maur-des-Fossés site, in France, boosting local competitiveness and driving economic growth.
This investment demonstrates Septodont’s commitment to its manufacturing footprint in France and will support the local economic development with the creation of approximately 60 jobs.
